Amazing times we live in today. What was once thought to be “harmful” even “evil” illegal organic drugs are now being used for medicinal purposes. Of course, this has been a given already for marijuana, especially for some cancer patients. Now, however, psilocybin mushrooms or more bluntly, “shrooms” might soon follow in the footsteps of marijuana if you are looking to treat depression.
A new significant progress for psilocybin mushrooms has recently been made. The US Food and Drug Administration (FDA) has just given psilocybin mushroom therapy for treatment-resistant depression a Breakthrough Therapy status. That means they have indeed recognized the treatment’s significant potential for treating depression.
Still, the progress has only been made for the early clinical evidence, meaning further tests are still required before magic mushrooms become an official ammunition in the fight to treat depression, one of the most common psychological disorders. The treatment’s Breakthrough Therapy designation, allows for the FDA in assisting subsequent development and review, meaning it could only be a matter of time.
“The Breakthrough Therapy designation is a strong endorsement for the potential of psilocybin therapy. We look forward to learning more as further clinical studies are carried out, by our team at Imperial College as well as in COMPASS’s multi-center trial,” said Robin Carhart-Harris, head of the Psychedelic Research Group at Imperial College London.
Should more progress be made proving further medical benefits for psilocybin mushrooms, its restrictive Schedule 1 category drug control may soon be removed or redesignated. That should make it more accessible for research and other potentially beneficial uses other than to treat depression.